Leading pharmaceutical company Eli Lilly has completed Phase II clinical trials for Donanemab, a promising Alzheimer's treatment. Researchers report highly encouraging results, with the drug significantly reducing beta-amyloid protein deposits in the brain—a key driver of cognitive decline.
The World Health Organization (WHO) estimates Alzheimer's affects about 50 million people worldwide, with roughly 10 million new cases each year. As the leading cause of dementia—accounting for 60 to 70% of cases—it remains a primary driver of disability and dependency among older adults.
On January 11, 2021, Eli Lilly announced in a press release the completion of Phase II trials for Donanemab. These results offer a source of hope for patients after decades of unsuccessful treatment efforts.
The study enrolled 272 patients with early-stage Alzheimer's. Over 76 weeks, Donanemab reduced beta-amyloid deposits by 32% compared to the placebo group, underscoring the drug's potential effectiveness.
Eli Lilly officials highlighted symptom reductions, including significant improvements in cognitive function and daily living activities—though not all endpoints showed benefits. The company is now advancing to Phase III, enrolling no less than 500 participants.
Earlier, in 2019, NeuroEM Therapeutics conducted a small trial on 8 patients using electromagnetic waves delivered through the skull to target cognitive symptoms.
